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Abstract
Objetive: Thrombospondin-1 serum levels is correlate with pelvic pain in patients with ovarian
endometriosis.
Patients: Thrombospondin-1 serum levels were prospectively analysed in 51 patients (group A
asymptomatic patients or patients presenting mild dysmenorrhea and women comprised group B
severe dysmenorrhea and/or chronic pelvic pain and/or dyspareunia) who underwent surgery for
cystic ovarian endometriosis to asses whether a correlation exists among thrombospondin-1
serum levels and pelvic pain.
Results: From 56 patients, five cases were ultimateley excluded, because the histological diagnosis
was other than cystic ovarian endometriosis (2 teratomas and 3 haemorragic cysts). The mean
thrombospondin-1 serum levels in group A was 256,69 pg/ml_+37,07 and in group B was 291,41
pg/ml + 35,59.
Conclusion: Pain symptoms in ovarian endometriosis is not correlated with thrombospondin-1
serum levels.
Introduction
Endometriosis is a common gynaecologic disease of
unknown aetiology. The most widely accepted hypothesis
for the development of endometriosis is retrograde men-
struation. However, some other factor renders certain
women susceptible to the implantation and growth of this
ectopic endometrium.
Angiogenesis appears as one of the processes involved in
the pathogenesis of endometriosis [1,2]. Angiogenic fac-
tors are increased in the peritoneal fluid of patients with
endometriosis [3,4] in peritoneal implants [5] and in
ovarian endometriomas[6,7].
On the other hand some investigators have found that
angiogenesis is related to pelvic pain [8]. We speculated
that ovarian endometriomas in patients presenting with
pelvic pain would have more angiogenesis than those in
asymptomatic women and, therefore, their vascular fea-
tures would be different [9]. Previosly, we studied ang-
iogenic factors (VEGF, IL-8) and their relationship with
pelvic pain and conclude that these angiogenic factors not
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correlate with pelvic pain in ovarian endometriosis [10-
13].
Angiogenesis is under the control of numerous inducers,
including the vascular endothelial growth factor (VEGF)
family and inhibitors, such as thrombospondin-1 (TSP-1)
[9]
The aim of our study was to further investigate throm-
bospondin-1 serum levels in asymptomatic patients and
women with pelvic pain to determine whether this antian-
giogenic factor can be used as a serum marker of endome-
triosis activity.
Patients
Materials and methods
In this prospective study 56 pre-menopausal women
(mean age: 34.38 ± 7.07) were enrolled from February
2003 to February 2005. Patients were divided in two
groups according to clinical complaints. Group A
included asymptomatic patients or patients presenting
mild or moderate dysmenorrhea, but without dispareunia
or chronic pelvic pain (n = 25) Group B included patients
presenting severe dysmenorrhea (with no response to
conventional analgesic, treatment such as antiprostaglan-
dins and requiring bed rest) and/or dyspareunia and/or
chronic pelvic pain. (n = 26). The degree of pain was
established using a visual analogue scale, VAS scale [14].
All patients provided informed consent after the nature of
the study was fully explained and Institutional Review
Board approval (Clinica Universitaria de Navarra) was
obtained before starting the study.
Blood samples were collected from all patients before
anaesthesia by venipuncture into 10 cc sterile tubes and
were kept at room temperature until centrifugation at 400
×  g  for 10 minutes. Less than 2 hours were allowed
between blood collection and processing. Serum aliquots
were then frozen at -80°C until measurement of throm-
bospondin-1 serum levels.
Serum concentrations of thrombospondin-1 were meas-
ured with use of an immunoassay (Quantikine; R&D Sys-
tems Inc., Minneapolis, MN). Thrombospondin-1
concentration can be measured in the range of 3.5 to
2,000 pg/mL. Interassay and intra-assay coefficients of
variation were <10%.
Statistical analysis
Statistical analysis was performed using the SPSS version
11.0 software (SPSS, Inc., Chicago IL). The mean serum
level of thrombospondin-1 was compared in two groups
using the Student's t-test for independent samples.
All results of thrombospondin-1 expression were analysed
by the Student's t-test. Spearman's correlation coefficient
was used to evaluate the relationship between parameters.
Statistical significance was set at p < 0,05.
Results
From 56 patients, five cases were ultimateley excluded,
because the histological diagnosis was other than cystic
ovarian endometriosis (2 teratomas and 3 haemorragic
cysts). The presence and type of pelvic adherences, mean
rAFS score and stages, and sizes of endometriomas were
not statistically different between groups [15].
The mean thrombospondin-1 serum levels in group A was
256,69 pg/ml_+37,07 and in group B was 291,41 pg/ml +
35,59. In order to verify whether this observation could
have been biased by the lack of control for several possible
confounders, the mean thrombospondin-1 serum levels
was adjusted with respect to gravidity, length of menses,
infertility and BMI in a univariate general linear model
[16]. Using this model, no significant difference was
observed in mean thrombospondin-1 serum levels
between two groups.
Serum thrombospondin-1 concentration did not correlate
with the diameter of the endometriomas and the severity
of the endometriosis, assessed according to revised AFS
scores.
Conclusion
The presence of ovarian cystic endometriosis is associated
with pelvic pain in women suffering this disease [8]. On
the other hand, angiogenic factors have been found
increased in ovarian endometriomas [6]. Angiogenesis is
related to vascularization. Therefore, a correlation
between vascularization and the presence of pelvic pain
might be assumed. Some studies assessing angiogenic
activity in endometriosis have used either morphometric
or inmunohistochemical techniques in endometriotic tis-
sue [6,17-19]. Other studies have evaluated vascular activ-
ity measuring serum [16,20] or peritoneal fluid
concentrations of angiogenic factors, such as VEGF [1,3].
Previously, some authors assessed that angiogenic factors
are increased in the serum of patients with endometriosis
[18] when compared with patients without endometrio-
sis. Recently, Ohata has been demostrated that throm-
bospondin-1 serum levels were higher in patients with
ovarian endometrioma than in patients without endome-
triosis [21,22].
Previously, we demonstrated for the first time that IL-8
and VEGF serum levels is not increased in patients diag-
nosed of ovarian endometriomas who presenting pelvic
pain as compared with those who are asymptomatic.
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TSP-1 is higher in endometriotic lesions and is associated
to the extent of their vascularization.
In the present study, we analysed if thrombospondin-1
serum levels were correlated with ovarian endometrisosis
and pelvic pain. We conclude that although throm-
bospondin-1 seems to play a key role in the local develop-
ment of endometriotic lesions, the disease is not
associated with a significant modulation in the levels of
circulating thrombospondin-1 and the activity of
endometriosis can not be monitored using serum levels.
Although recently studies have demonstrated that IL-8
and thrombospondin-1 serum level improve diagnostic
reability of ovarian endometriosis we believe that the
optimal serum marker should be used to monitoring the
response of new antiangiogenic agents used in endometri-
osis treatment.
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